Sanofi’s SNY vaccines division, Sanofi Pasteur, announced that its dengue vaccine, Dengvaxia, has gained regulatory approval in Mexico, marking the first vaccine to be licensed for the prevention of dengue.
Dengvaxia has been approved for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, between 9 and 45 years of age living in endemic areas.
The company has begun manufacturing Dengvaxia in France and the first doses have already been produced.
According to the WHO, 400 million people are affected by dengue every year in the world.
We remind investors that Sanofi possesses one of the world’s leading vaccine operations. The company’s portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi also enjoys a strong position in both seasonal and pre-pandemic influenza vaccine markets. The company intends to launch five vaccines by 2020.
Revenues at the vaccine segment were $3.3 billion in the first nine months of 2015.
Meanwhile, Sanofi continues to progress with its other vaccine candidates in its pipeline. Currently, the company has three late-stage vaccine candidates in pipeline – clostridium difficile (Toxoid vaccine), rotavirus (rotavirus oral vaccine), and VaxiGrip QIV IM (influenza vaccine)
Moreover, the company expects regulatory approval from the Center for Biologics Evaluation and Research for its pediatric hexavalent vaccine, PR5i vaccine, this quarter, while a response from the European Commission for the same is expected in the second quarter of 2016.
Sanofi currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the health care sector include Achillion Pharmaceuticals, Inc. ACHN, Anika Therapeutics Inc. ANIK and Corcept Therapeutics Incorporated CORT, each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment